Glucosamine Knee Osteoarthritis Meta-analysis: What the Evidence Says

Quick Answer

Glucosamine Knee Osteoarthritis Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 research article.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Non-steroidal anti-inflammatory drugs (NSAIDs), as first-line pharmacological agents, provide symptomatic improvement but are associated with gastrointestinal bleeding and cardiovascular risks upon prolonged administration. [Shi Chuankai (2026); evidence level 1]
• Systematic reviews and meta-analyses of observational studies indicate substantial heterogeneity in NSAID utilization among OA patients, with generally limited evidence quality. [Shi Chuankai (2026); evidence level 1]
• In fact, CS/CS+GLU and glucosamine were not associated with an increased risk of adverse events (AE) compared to placebo.This good tolerability of CS/CS+GLU contrasts with the toxicity problems described for NSAIDs/COXIBsat gastrointestinal,cardiovascular,,cerebrovascularand renallevels. [Rubio-Terrés Carlos (2026); evidence level 4]
• A 2019 studyinvolving more than 7,000 patients with osteoarthritis showed they had a 23% increased risk of developing cardiovascular disease compared to controls; and that a 41% increase in this risk was directly linked to NSAID use. [Rubio-Terrés Carlos (2026); evidence level 4]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For glucosamine knee osteoarthritis meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Shi Chuankai (2026). Efficacy and safety of different curcumin formulations in osteoarthritis: an umbrella review of systematic reviews. DOI: 10.3389/fmed.2026.1801273. PMCID: PMC13233388. PMID: 42254374. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13233388/
• Rubio-Terrés Carlos (2026). Cost-Effectiveness of Chondroitin Sulphate (with or without Glucosamine) Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs. DOI: 10.2147/CEOR.S577731. PMCID: PMC13157842. PMID: 42117079. License: https://creativecommons.org/licenses/by-nc/4.0/ https://www.dovepress.com/terms.php http://creativecommons.org/licens.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13157842/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.